Ranolazine, a partial fatty acid oxidation (pFOX) inhibitor, improves left ventricular function in dogs with chronic heart failure.

@article{Sabbah2002RanolazineAP,
  title={Ranolazine, a partial fatty acid oxidation (pFOX) inhibitor, improves left ventricular function in dogs with chronic heart failure.},
  author={Hani N. Sabbah and Margaret P. Chandler and Takayuki Mishima and George S Suzuki and Pervaiz A. Chaudhry and Omar Nass and Brandon J. Biesiadecki and Brent K. Blackburn and Andrew I. Wolff and William Chad Stanley},
  journal={Journal of cardiac failure},
  year={2002},
  volume={8 6},
  pages={
          416-22
        }
}
BACKGROUND Abnormalities of energy metabolism are often cited as key elements in the progressive worsening of left ventricular (LV) dysfunction that characterizes the heart failure (HF) state. The present study tested the hypothesis that partial inhibition of fatty acids will ameliorate the hemodynamic abnormalities associated with HF. METHODS AND RESULTS Chronic HF (LV ejection fraction 27 +/- 1%) was produced in 13 dogs by intracoronary microembolizations. Hemodynamic and angiographic… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 68 CITATIONS, ESTIMATED 54% COVERAGE

Ranolazine Attenuates Trastuzumab-Induced Heart Dysfunction by Modulating ROS Production

  • Front. Physiol.
  • 2018
VIEW 4 EXCERPTS
CITES BACKGROUND & RESULTS
HIGHLY INFLUENCED

Role of ranolazine in angina, heart failure, arrhythmias, and diabetes.

  • Pharmacology & therapeutics
  • 2012
VIEW 3 EXCERPTS
CITES BACKGROUND & RESULTS
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

2004
2018

CITATION STATISTICS

  • 3 Highly Influenced Citations